Accessibility Statement

We are committed to providing a website that is accessible to the widest possible audience. To do so, we are actively working with consultants to update the website by increasing its accessibility and usability by persons who use assistive technologies such as automated tools, keyboard-only navigation, and screen readers.

We are working to have the website conform to the relevant standards of the Section 508 Web Accessibility Standards developed by the United States Access Board, as well as the World Wide Web Consortium's (W3C) Web Content Accessibility Guidelines 2.1. These standards and guidelines explain how to make web content more accessible for people with disabilities. We believe that conformance with these standards and guidelines will help make the website more user friendly for all people.

Our efforts are ongoing. While we strive to have the website adhere to these guidelines and standards, it is not always possible to do so in all areas of the website. If, at any time, you have specific questions or concerns about the accessibility of any particular webpage, please contact WebsiteAccess@tenethealth.com so that we may be of assistance.

Thank you. We hope you enjoy using our website.

Skip to Main Content

Clinical Trials

Now Enrolling

BAROSTIM NEO® - BEAT-HF

Baroreflex Activation Therapy for Heart Failure

Principal Investigator: Dr. Forman

A trial for heart failure patients with reduced ejection fraction. Subjects are randomized to receive either Barostim activation therapy with the Barostim neo system/medical management or to receive medical management alone.

An Investigation of the Role of Germ-line Mutations in Cancer Predisposition, Tumor Biology and Response to Treatment
Principal Investigator: Dr. Kwon

A study to find and confirm genetic or inherited differences between cancer patients, to help us learn how to best treat cancer patients with radiation.

Upcoming Studies

1. A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects with Staphylococcus aureus Bacteremia Including Infective Endocarditis.

Principal Investigator - Dr. Schneider

A trial to compare telavancin to standard IV therapy in the treatment of S. aureus  bacteremia, and S. aureus  right-sided infective endocarditis.

2. Genetic Variation, Stress, & Functional Outcomes after Stroke R Rehabilitation (STRONG) 

Principal Investigator - Dr. N. Patel

A trial for those affected by a stroke.  STRONG will examine how stress and genetics can affect rehab after stroke.

3. Atrial Cardiopathy & Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)

Principal Investigator - Dr. N. Patel

A trial for those affected by a stroke.  STRONG will examine how stress and genetics can affect rehab after stroke.

Approved Humanitarian Use Devices (HUD)

1. Codman Enterprise Vascular Reconstruction Device & Delivery System
Principal Investigator -Dr. Farid
2. Graftmaster RX Coronary Stent Graft System
Principal Investigator-Dr. Fischer
3. Neuroform Microdelivery Stent System
Principal Investigator-Dr. Farid
4. Wingspan Stent System with Gateway PTA Balloon Catheter
Principal Investigator-Dr. Farid

For further information, contact Margaret Villa RN, 562-799-3104